RT Journal Article
SR Electronic
T1 Clinical Outcomes of Resectable Esophageal Cancer with Supraclavicular Lymph Node Metastases Treated with Curative Intent
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3741
OP 3749
VO 37
IS 7
A1 HONMA, YOSHITAKA
A1 HOKAMURA, NOBUKAZU
A1 NAGASHIMA, KENGO
A1 SUDO, KAZUKI
A1 SHOJI, HIROKAZU
A1 IWASA, SATORU
A1 TAKASHIMA, ATSUO
A1 KATO, KEN
A1 HAMAGUCHI, TETSUYA
A1 BOKU, NARIKAZU
A1 UMEZAWA, REI
A1 ITO, YOSHINORI
A1 ITAMI, JUN
A1 KOYANAGI, KAZUO
A1 IGAKI, HIROYASU
A1 TACHIMORI, YUJI
YR 2017
UL http://ar.iiarjournals.org/content/37/7/3741.abstract
AB Background: In the seventh edition of the Union for International Cancer Control (UICC) TNM classification, supraclavicular lymph node (SCLN) in regard to thoracic esophageal cancer (EC) is regarded as a distant organ, therefore, if resectable, SCLN metastasis is considered a candidate for systemic chemotherapy. The purpose of this study was to clarify the survival outcome in patients with resectable thoracic EC with SCLN metastases (M1LYM) treated with curative intent. Patients and Methods: Clinical outcomes in patients with resectable thoracic EC with SCLN metastases (M1LYM) treated by esophagectomy or definitive chemoradiotherapy (dCRT) were retrospectively analyzed. Results: A total of 102 patients were divided in three groups: Surgery with perioperative therapy, n=45; surgery alone, n=19; and dCRT, n=38. Overall, median progression-free survival and median survival time were 9.3 and 26.7 months, respectively. The median survival time was 27.5 months in the group treated with surgery with perioperative treatment, 50.6 months in those treated with surgery alone, and 22 months in the dCRT group. No significant survival difference was seen among the three groups. Conclusion: Over 30% of patients with resectable M1LYM treated with curative intent achieved long-term survival.